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Summary
Background: Refractory sprue (RS) is a rare and seve-
re celiac-like enteropathy not responding to a strict glu-
ten-free diet. Although prognosis is generally poor, lit-
tle is known about the long-term outcome of patients.
Aim: to report baseline characteristics and long-term
outcome of a series of patients diagnosed and treated in
a single institution. Materials: We report a retrospec-
tive cohort of 25 consecutive patients (15 females;
mean age 46 yr; range 28-71) diagnosed with RS ba-
sed on the presence of a non-responsive celiac-like ente-
ropathy. All patients were intensively treated with a
gluten-free diet, steroids, nutritional support and im-
munosupression. Results: Clinical and biological cha-
racteristics of patients suggest that, at least, 24 patients
had clear evidences of celiac disease. HLA DQ2/DQ8
genes were present in all the 24 patients typed and au-
toimmune enteropathy was excluded in all. According
to the genotyping, 12 patients had a polyclonal lymp-
hocyte population (RS type I) and 13 exhibited mono-
clonal TCR-γ gene rearrangements (RS type II). Six-
teen patients had evidence of ulcerative jejunitis (UJ)
(7 in RS type I and 9 in type II). Overall median fo-
llow-up time after diagnosis of RS was 29 mo/patient
(range 7 to 204) (45 mo for type I and 24 mo for ty-
pe II). Overall mortality was 48% (12 patients), 6 in
each type. Eight patients with UJ (50%), 3 with
lymphoma (two T-cell and one B-cell type) and 4
(44%) without ulcers died during follow-up. The cau-
ses of death were sepsis in the context of a progressive
deterioration but without overt malignancies (n=5),
vascular causes (n=3) and severe malnutrition (n=1).
Three- and 5-yr survival rate after diagnosis of RS for
the overall population was 60% and 56%. There was
no differences between type I (67%, 58%) and type II
RS patients (54% for both periods). Patients with UJ
had lower but non-significant 3- and 5-yr survival ra-
tes (56% and 50%, respectively) compared with pa-
tients without ulcers (78% and 66%). Survivors had
a favorable outcome. While 11 patients persists asymp-
tomatic, two other cases still have mild diarrhea and
one low body weight. Conclusions: We confirm that
RS is a severe celiac disease-related disorder with very
high mortality. Diagnosis of overt lymphoma (12%)
in our long-term follow-up was not as frequent as was
reported by other groups. A proportion of patients per-
sist in good health for a long time irrespective of the
nature of the IEL infiltration or the presence of UJ. 
Resumen
Características clínicas y evolución a largo plazo
de una serie de pacientes con sprue refractario
diagnosticados en una sola institución
Introducción: El sprue refractario (SR) es una rara
y severa entidad consistente en una enteropatía tipo
celíaca que no responde a una estricta dieta libre de
gluten. Aún cuando el pronóstico es generalmente
pobre, poco  es  conocido acerca de la evolución de los
pacientes a largo plazo. Objetivo: reportar las caracte-
rísticas clínicas y la evolución a largo plazo de una
serie de pacientes diagnosticados y tratados en una sola
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institución. Materiales: Reportamos una cohorte
retrospectiva de 25 pacientes consecutivos (15 mujeres;
edad media 46 años; rango 28-71) diagnosticados
como SR sobre la base de una enteropatía tipo celíaca
que no respondió a la dieta libre de gluten. Todos los
pacientes recibieron un tratamiento intensivo consis-
tente en dieta libre de gluten, alimentación enteral o
parenteral, corticosteroides e inmunosupresión.
Resultados: Los elementos clínicos y biológicos sugieren
que 24 pacientes exhibían claras evidencias de enfer-
medad celíaca. Los genes HLA DQ2/DQ8 estuvieron
presentes en los 24 pacientes estudiados y se excluyó la
enteropatía autoinmune en todos los casos. De acuerdo
al genotipo, 12 pacientes presentaron una población
linfocitaria intraepitelial policlonal (SR tipo I) y 13
exhibieron un rearreglo genético monoclonal del TCR-
γ (SR tipo II). Dieciséis pacientes presentaron eviden-
cias de yeyunitis ulcerativa (YU) (7 en SR tipo I y 9 en
el tipo II). El tiempo promedio de seguimiento luego
del diagnóstico de SR fue 29 meses/paciente (rango 7 -
204) (45 y 24 meses para tipo I y tipo II, respectiva-
mente). La mortalidad global fue del 48% (12 pacien-
tes), 6 en cada tipo de SR. Ocho pacientes con YU
(50%) murieron durante el seguimiento, 3 con linfo-
ma (dos de células T y uno de células B) y cuatro
(44%) individuos sin úlceras también fallecieron. Las
causas de muerte fueron vasculares (n=3), sepsis en el
marco de deterioro progresivo sin desarrollo de malig-
nidad (n=5) y desnutrición progresiva (n=1). La tasa
de sobrevida a 3 y 5 años luego del diagnóstico de SR
fue de 60% y 56%, respectivamente, sin observarse
diferencias entre pacientes con SR tipo I (67%, y 58%)
y tipo II (54% para ambos períodos). Los pacientes con
YU tuvieron  tasas menores de sobrevida a 3 y 5 años
(56% y 50%, respectivamente) comparadas con las
exhibidas por pacientes sin úlceras (78% y 66%).
Once pacientes evolucionaron favorablemente encon-
trándose asintomáticos, dos pacientes persistieron con
diarrea y otro permaneció con bajo peso.
Conclusiones: Nuestros resultados confirman que el
SR es una patología grave relacionada con la enferme-
dad celíaca presentando una muy elevada mortalidad.
El diagnóstico de linfoma (12%) en el largo plazo de
seguimiento de nuestro estudio no fue tan frecuente
como ha sido reportado por otros grupos. Una propor-
ción de pacientes persisten en buen estado de salud en
el largo plazo independientemente de la naturaleza de
la infiltración de LIE ó la presencia de YU. 
Celiac disease (CD) is an autoimmune entero-
pathy produced by intolerance to dietary gluten in
genetically predisposed individuals where clinical
and mucosal abnormalities improve or normalize by
exclusion of gluten from the diet.1 The disease is
characterized by an increased risk for complications
and associated disorders.2 Refractory sprue (RS) is a
rare condition characterized by a severe malabsorp-
tion syndrome as a consequence of a celiac-like
enteropathy not responding to a gluten-free diet
(GFD).2,3 Non-responsiveness may be secondary,
when patients have proved CD and previously res-
ponded to gluten withdrawal but subsequently
develop symptoms despite strict dietary complian-
ce, or primary, when the patient initially fails to res-
pond to strict avoidance of gluten following diag-
nosis.4,5 In every case, other causes of refractoriness
should be excluded such as continued gluten intake
(the most common cause),6 the presence of small
bowel bacterial overgrowth, exocrine pancreatic
insufficiency or dietary intolerance to food proteins
other than gluten (soy or cows’ milk protein).5,6 In
other circumstances, a different diagnosis such as
collagenous enteritis or colitis, autoimmune entero-
pathy or enteropathy-associated T-cell lymphoma
(EATL) must be explored.5-8
Clinical, laboratory and immunopathological fin-
dings have suggested that a substantial proportion
of these patients show clear evidence of having CD
before the diagnosis of RS.5 In contrast, despite the
existence of the typical celiac HLA genotype, diag-
nosis of CD in other patients cannot be reasonably
supported on the bases of serology, clinical features
and/or histology.5 Very elegant studies from. Cellier
et al.8,9 have shown that most RS patients (>75%)
are characterized by the presence of a non-lympho-
matous (normal cytological appearance) but abnor-
mal subset of intraepithelial lymphocyte (IEL)
population containing CD3ε and restricted rearran-
gement of the TCRγ chain but lacking the surface
expression of T-cell receptors. Interestingly, this
immunophenotype is identical to that of EATL
lymphocytes and suggests that the aberrant IEL
population present in ulcerative jejunitis (UJ) and
RS constitutes an evidence of a neoplastic T-cell
disorder (RS type II).8-11 Studies have shown that a
minority of patients with RS patients have a poly-
clonal, phenotypically not aberrant repertoire of
IEL (RS type I).12
Most series agree that the very poor prognosis of
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patients with type II RS is due to EATL with a very
aggressive clinical course.9-13 In contrast, despite
refractoriness to a GFD, most authors suggest that
patients with a polyclonal IEL population (type I)
often respond to additional therapeutics such as the
use of dietary measures (enteral and/or parenteral
nutrition) and aggressive pharmacological approa-
ches (steroids and immunosuppressive agents)
(9,14,15). Knowledge about the long-term outco-
me in patients with RS is hindered for several rea-
sons. Mostly relevant is the scanty number of
patients reported in different series treated with very
different therapeutic schedules. In addition, the
potential for selection bias exists in retrospective
series. Our aims in this study are to evaluate clinical
presentation, baseline characteristics and long-term
clinical course of a non-selected series of patients
with RS assessed and followed-up using a very strict
diagnostic and treatment protocol in a single ter-
tiary referral center.
Patients and methods
Patients. The present report is a retrospective analy-
sis of the baseline characteristics and the outcome of
a series of consecutive patients diagnosed with RS in
a tertiary referral centre. Between 1987 and 1999
we diagnosed RS in 25 patients (15 female and 10
male; median age 46 yr, range 28-71 yr). Diagnosis
of RS was based on the presence of an initial (pri-
mary RS) or subsequent (secondary RS) failure of a
strict GFD to restore normal intestinal structure
and function in patients who have a celiac-like en-
teropathy.2 We arbitrarily consider a 6-months GFD
period as reasonable to await clinical and histologi-
cal improvement before making a diagnosis of RS.
Patients with a primary RS were put on intensive
treatment before the rule of 6-months on a GFD
due to the profound clinical deterioration, lack of
response to a GFD and the presence of UJ. After
suspicion of RS, patients were exhaustively explored
to determine the presence of lymphoma and a 6-
month period was employed in order to await for a
malignant complication before a definitive diagno-
sis. We estimated the onset of refractoriness from
the time of initiation of an alternative therapy (ste-
roids as a first line) due to lack of response to a
GFD.
Suspicion of CD was based on the presence of cli-
nical features, a characteristic celiac enteropathy,1
the presence of a positive CD-related serology and
the response to strictly monitored GFD. The onset
of symptoms of CD was estimated based on the age
reported for appearance of symptoms. At the initial
diagnostic work-up for a potential RS, patients we-
re exhaustively explored for any significant disorder
associated with refractoriness (e.g. associated endo-
crine disorder, pancreatic insufficiency, small bowel
bacteria overgrowth, etc.). Patients were systemati-
cally explored for CD-related serology (antigliadin
antibodies –AGA- type IgA and IgG), antiendomy-
sial antibodies (EmA), anti-tissue transglutaminase
antibodies (a-tTG). The presence of autoimmune
enteropathy was excluded by the absence of serum
evidence of anti-enterocyte autoantibodies.16 Fi-
nally, before definitively categorizing patients as re-
fractory to dietary measurements, alimentary beha-
viors were strictly monitored by expert physicians
and nutritionists. 
Endoscopic procedures and histological assessment.
Histological diagnosis of CD in 24 patients was per-
formed based on the analysis of intestinal biopsy
samples obtained through endoscopic procedures.
The initial diagnosis of patient # 25 was done by je-
junal biopsy samples obtained using a multipurpose
biopsy capsule (Bolt, French, Pollard). Duodenos-
copy and push enteroscopy were performed using
commercial videoendoscopes (Pentax, Japan) and
several small intestinal biopsy samples (n>6) were
obtained in the same procedures with endoscopic
forceps. Samples were either fixed in 10% formalin
for conventional histological and immunophenoty-
pic assessment or snap-frozen in liquid nitrogen.
Characterization of histological findings was perfor-
med using the modified Marsh´s classification
which categorizes mucosal abnormalities as: type 0
(normal), type I (intraepithelial lymphocytosis), ty-
pe II (lymphocytosis and moderate crypt hyperpla-
sia) or type III (IIIb subtotal atrophy; IIIc total vi-
llous atrophy).1 Intraepithelial lymphocyte count
was expressed as percentage of lymphocytes per 100
epithelial cells.    
Patients exhibited symptoms for a median of 48
mo. (range 3-560) before suspicion of CD. All pa-
tients had classical symptoms of GI compromise be-
fore suspicion of CD and most relevant symptoms
were: chronic diarrhea in 20 and malnutrition in 5
cases. Due to the severity of symptoms, 21 patients
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had required diagnostic procedures and intensive
treatments on an inpatient basis before diagnosis of
CD. When RS was suspected, all patients under-
went small bowel double-contrast radiological exa-
minations and CT scans to determine structural ab-
normalities of the small intestine. If these examina-
tions suggested the presence of masses, enlarged
lymph nodes or ulcers, an enteroscopy and/or a la-
parotomy were subsequently performed. Thus, 12
enteroscopies and 13 laparotomic procedures
(which included partial resection of affected seg-
ments or systematic resections of apparently non-af-
fected jejunal and ileal segments) were done. While
19 patients had at least one of these procedures per-
formed, 6 other with no evidence of morphological
abnormalities did not require additional studies.
Specialized determinations and procedures
Serology determinations. Determinations of anti-
gliadin (AGA) (IgA and IgG subtypes) and anti-tis-
sue transglutaminase antibodies were performed by
an ELISA method, as previously reported, using
commercial kits (INOVA Diagnostics Inc.; CA;
USA).17 Endomysial antibodies were determined by
indirect immunofluorescence on monkey esophagus
substrate (INOVA Diagnostics Inc.; CA; USA).17
Antienterocyte antibodies were determined by a ho-
memade indirect immunofluorescence method
using human small intestinal substrate.16 Fecal α1-
antitrypsin clearance was determined using radial
immunodifussion, as previously reported.18
Molecular analysis. DNA was extracted from paraf-
fin-embedded or frozen samples by proteinase K di-
gestion and phenol-chloroform purification, preci-
pitated with ethanol and resuspended in 10 mmol/L
Tris and 1 mmol/L EDTA. All samples gave a detec-
table product of 274 pb from DRβ gene after am-
plification with primers PSP-49 and Amp-A.20 We
amplified rearranged TCR genes by polymerase
chain reaction (PCR) as a useful strategy to establish
clonality in biopsy material.21 Amplification reac-
tions were performed with 250 ng of DNA in a
50µL reaction that contained 16.6 mM ammonium
sulfate, 67 nM Tris-HCl pH 8.8, 10 mM β-mercap-
toethanol, 2.0 mM MgCl2, 200 µg/mL gelatin,
200 µM each dNTP, 25 pmol of each primer and 1
U Taq polymerase. Temperature conditions were 90
sec at 94º C, and 120 sec at 72º C for mixes I plus
III, during 45 cycles. Staining was performed with
ethidum bromide and was visualized under ultravio-
let light. Pooled primers in mixes I and III and the
respective sequences were as previously published.21
Genomic DNA was also extracted from whole
blood and amplified with the allele-specific primer
sets and an internal control primer set specific for
human G3PDH gene using a MJ research PT100
thermal cycler (MJ Research Inc. Watertown, MA,
USA), followed by the high-resolution PCR-SSP ty-
ping procedure above referred.
HLA class II typing. Alleles of either DQ2 or DQ8
molecules primary associated with CD susceptibi-
lity were typed in DNA samples from 24 patients
following protocols from a commercial DQB1*
"high resolution" PCR-sequence specific primers
typing kit (Fastype System, Bio Synthesis).22
Outcome assessment and treatment
All patients were followed-up by physicians and
nutritionists expert in malabsorption, CD and RS.
They were periodically re-evaluated and clinical, la-
boratory, and tests assessing the morphology of ab-
dominal organs (small bowel double-contrast stu-
dies, ultrasound and CT scan) were considered ac-
cording to demand. Treatment consisted in a strict
GFD periodically monitored including serology and
intestinal biopsy. After the diagnosis of RS patients
continued on a GFD and all except one case received
oral and/or parenteral steroids (oral prednisone: 1
mg/kg body weight/day [n=23]; i.v. hydrocortisone:
4.5 mg/kg body weight/day [n=12] followed by oral
prednisone at equivalent doses). Based on a 2 month
demonstrated lack of response of these therapeutic
measures, 13 patients were started on azathioprine (2
mg/kg body weight/day p.o., administered b.i.d.),
two on cyclosporine (5 mg/kg body weight) and one
on 6-mercaptopurine (1.5 mg/kg body weight/day)
(due to secondary effects by the use of azathioprine).
Doses of steroids were tapered after 2 months on
azathioprine, cyclosporine or 6-mercaptopurine ad-
ministration according to the theoretical onset of the
effect of the immunosupression drug. A small group
of these cases (n=7) have been reported in an open-
label trial assessing the use of azathioprine in RS.23
Statistics
Results are expressed as mean ± standard error of
the mean (SEM) or median and range; and analyzed
with t test (paired and unpaired), Fisher´s exact,
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Mann-Whitney ranked sum test and Wilcoxon sig-
ned rank test as appropriate. A p value <0.05 was
considered significant. Three- and five-yr survival
rates were calculated according to conventional for-
mula. Survival for patients with and without ulcers
was calculated from the time of diagnosis of UJ.
Survival for patients with and without the aberrant
IEL infiltration was calculated from the estimated
onset of overt symptoms of CD, the time of diagno-
sis of CD and the estimated onset of refractoriness.
The actuarial percentage of survival was expressed
by Kaplan-Meier curves and the differences assessed
by the Mantel-Haenzel log-rank test. The propor-
tion of patients with complications was compared
by calculation of odds ratios and 95% CI. Statistical
analysis was performed using Statistix 7.0 (Analyti-
cal Software, Tallahassee, FL, USA).
Results
Baseline data of patients
Clinical aspects. Table 1 shows clinical and bioche-
mical characteristics of RS patients at diagnosis.
Presence of weight loss (n=25), chronic diarrhea
(n=24), abdominal pain (n=20) and fever (n=10)
were the most prevalent findings. According to the
clinical assessment, 13 patients were categorized as
having a primary RS and 12 as secondary RS. Th-
ree patients had a first-degree relative with CD. At
diagnosis of RS, patients had a low mean hemoglo-
bin level (11.2 mg/dL, range 8.5 to 16.5) (17 pa-
tients had values below 12 g/dL), low mean serum
albumin (2.4 g/dL, range 0.9 to 4.3) (21 patients
had values below 3.5 g/dL), low body mass index
(19.4 kg/m2, range 14.9 to 27.1) and increased fe-
cal α1-antitrypsin clearance 105 mL/day, range 12
to 652).
At diagnosis, all patients underwent duodenos-
1 GS 29 F 9,5 1,49 169 15,6         -        + + Yes Yes Yes       B1 201/501
2 TP 50 F 11,5 1,77 66,2 18,9         - + - Yes —           Yes       B201/302
3 MA 46 F 9,5 3,3 80,5 15,3         - + - Yes Yes —       B1604/501
4 LD 31 M 12,3 4,02 79 14,9         - + + Yes Yes —       B1201/203
5 JA 58 F 9,3 0,96 71,4 18,9         - - - Yes — Yes       B1201/501
6 SR 38 F 8,5 2,48 97,2 18,5         +       + - Yes Yes Yes       B1303-6/302-7-8
7 MS 53 F — 1.29 102 19.4         +      + - Yes — Yes       ND
8 JC 54 M 12,6 1,79 386 27,1         - - + Yes — Yes       B1201/202-302
9 AS 45 F 11,6 2,4 109 18.0         +       - - Yes — Yes       B1201/202-302-A501
10 CE       45 M 14,7 4,3 105 21,1         -        - - — — Yes       B1201/202-302-A501
11 ZF 63 F 11 1,75 85,9 18.0         +     + - — — —       B1201/202
12 RG        50 M 16,5 4 130 19,4         -      - +      — — —        B1201/202-302-A201
13 JL 29 M 9,8 2,44 131,6 17,2         +     + - — Yes Yes       B1201/201
14 EP 54 F 11,2 1,29 332,5 21,5         -      - Yes Yes Yes       B1201/201
15 AM      44 M 9,5 0,9 460 19,3         +     + - Yes Yes —       B1201/201
16 AI 41 F 10 3,2 234 17,3         +     + + Yes Yes —       B1201/202
17 MDP    52 M 12,7 1,19 652 19,5         +     + + Yes Yes —       B1201/202 -A501
18 MEC    54 F 8,5 3,3 12 20,9         +     + - Yes Yes Yes       B1201/02-203- A501
19 MC       60 M 12,9 3,35 108,8 22,3         +     + + Yes Yes Yes       B1201/02-203- A501
20 MEM    53 F 9 2 20 14,9         +     + - Yes Yes —       B1201/02- A201-501
21 MCH    43 F 10 2,06 13,8 22,8         +     + + — — —       B1201/202
22 JV 53 F 12 3,4 349,7 19,4         -      + + — — —       B1302-306
23 JB 50 M 15,7 3,7 103,3 23,4         +     - + — — —       B1201/202
24 RO       61 M 10,7 2 122,9 19,3         -      + + — Yes —       B1202/301
25 FL 57 F 11 2,9 33,2 20,6         +     + - — — —       B1202/201
Age/         Hb         Alb   α1 AT CL    BMI    AGA   AGA                                          Entero       HLA
Patient     sex          g/dL       g/dL   mL/day     Kg/m2    -A      -G                                            scopy     DQ2-DQ8Ema U J    Surgery
Table 1. Some clinical, laboratory and genetic characteristics of refractory sprue patients assessed at diagnosis. Pa-
tients 1 to 13 were molecularly characterized as having a monoclonal TCR_ gene rearrangement (type II RS) and
patients #14 to #25 had a polyclonal intraepithelial lymphocyte population (RS type I). Hb: hemoglobin levels;
Alb: serum albumin; α1AT CL: fecal α1 antitrypsin clearance; AGA-A and AGA-G: antigliadin antibodies type
IgA and IgG, respectively; EmA: Antiendomysial antibodies type IgA; BMI: body mass index; UJ: diagnosis of ul-
cerative jejunitis. ND: not determined.
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copy for diagnostic and biopsy purposes.19 Twelve
patients (48%) underwent enteroscopy for assess-
ment and biopsy of ulcers suspected by radiology.
Overall, the combined analysis detected intestinal
ulcers in 16 patients. While, duodenoscopy eviden-
ced the presence of ulcers in six (36%), enteroscopy
evidenced ulcers in other five and surgery in five ad-
ditional cases. This analysis emphasizes the necessity
of a combined analysis for detection of ulcers. Ac-
cording to Marsh classification, baseline assessment
of intestinal mucosal morphology showed that 13
patients had type IIIc enteropathy, 11 had a type
IIIb lesion and one type IIIa. The median value of
intraepithelial lymphocyte count for RS patients
was 35%.(range 18%-55%).
Thirteen patients underwent exploratory laparo-
tomy based on the suspicion of anatomic abnorma-
lities (thickness of the intestinal wall, masses, enlar-
gement of lymphoid nodules, ulcers, etc.): 8 of the
RS type I subgroup and 5 of the RS type II sub-
group.  
Baseline data from patients with RS type I and ty-
pe II (table 2) did not show significant differences
in terms of symptoms, laboratory tests (hemoglo-
Table 2. Data of refractory sprue patients categorized according to the existence of a polyclonal (RS type I) or mo-
noclonal (RS type II) TCRγ rearrangement of intraepithelial lymphocytes (IELs) in intestinal mucosa. EmA: en-
domysial antibodies; Histological classification (see methods); Fecal α1AT Cl: fecal α1 antitrypsin clearance.
Parameters     
Time from the estimated onset of symptoms (mo.)
Median (range) 
Time from diagnosis of CD (mo.) Median (range)
Diarrhea (n of patients)
Fever (n of patients)
Ulcerative jejunitis (n of cases)
Body mass index (kg/m2) Median (range)
Hemoglobin (g/dL) Median (range)
Serum albumin (g/dL) Median (range) 
Fecal α1AT Cl (mL/day) Median (range)
EmA (n of positive cases)




LIEs count (%) Median (range)
3-yr Survival rate (%) 
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bin, serum albumin, fecal α1-antitrypsin clearance,
number of patients positive for EmA, histological
classification according to Marsh, % of IELs, and
number of patients with UJ. Patients with type II
RS had a lower BMI (p<0.06). Table 3 compares ba-
seline clinical, laboratory and histological data of
patients categorized as having or not diagnosis of
UJ. Once again, no differences were shown in most
assessed parameters. Compared with patients wit-
hout evidence of ulcers, those with UJ exhibited a
trend toward a lower body weight at diagnosis
(p<0.06) and mean serum albumin (1.9 g/dL vs. 2.9
g/dL; p<0.06).    
Specialized laboratory studies. At the time of diag-
nosis of CD and/or when a refractory enteropathy
was suspected, 11 patients had a positive EmA test
and/or a-tTG, 13 had positive IgA type AGA and
17 type IgG. Overall, 19 patients had IgA type
EmA and/or AGA and 22 had one or more positive
tests. 
Thirteen patients had a monoclonal TCR_ gene
rearrangement (type II RS) and 12 cases had a poly-
clonal lymphocyte population (RS type I). (table 1)
Interestingly, when findings from duodenal and je-
Table 3. Clinical and biochemical parameters of patients at baseline (diagnosis of RS) and outcome of patients
grouped according to the presence or absence of ulcerative jejunitis. EmA: endomysial antibodies; Histological clas-
sification (see methods); Fecal α1AT Cl: fecal α1 antitrypsin clearance.
Parameters
Time from the estimated onset of symptoms (mo.) Median (range)
Time from diagnosis of CD (mo.) Median (range)
Diarrhea (n of patients)
Fever (n of patients)
Abdominal pain (n of patients)
Monoclonal TCR γ (n of cases) 
Body mass index (kg/m2) Median (range)
Hemoglobin (g/dL) Median (range)
Serum albumin (g/dL) Median (range)
Fecal α1AT Cl (mL/day) Median (range)
EmA (n of positive cases)




LIEs count (%) Median (range)
3-yr Survival rate (%)
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junal samples were compared in the same patient,
both molecular genotypic characteristics concurred
in all cases.
Based on radiological, endoscopic and pathologi-
cal findings, 16 (64%) patients had multiple ulcers
in the small intestine, indicative ulcerative jejunitis.
Morphological characteristics of ulcer were widely
variable, ranging from an aphthous appearance to
big and profound lesions with sharp edges and den-
se fibrin. Interestingly, while 9 of 13 (69%) patients
with a monoclonal TCRγ receptor rearrangement
had evidence of UJ, 7 of 12 (58%) with polyclonal
lymphocytes also had ulcers. 
Considerations about diagnosis of celiac disease. Ba-
sed on the combined clinical information (familial
history, former response to a GFD, histological fin-
dings, etc.) and serology features, we estimate that
all patients had evidence of gluten sensitivity whet-
her or not they had evidence of response to a GFD.
If we exclude those cases only positive for AGA ty-
pe IgG (low specificity for CD) but without former
response to a GFD or familial features, we conclude
that 24 patients have concrete features indicative of
CD.
Outcome
General aspects. The initial clinical outcome of
most patients was characterized by a profound dete-
rioration. This was evidenced by the inability to
perform daily activities at the time of diagnosis
which required strict monitoring, support and treat-
ment on the inpatient basis in 20 patients. Surgical
approach in patients whe underwent laparotomy
did not avoid of complications with 4 patients re-
quiring re-explorations for abdominal sepsis or lea-
kage.
Median follow-up after diagnosis of RS for the
overall population was 29 mo/patient (range 7 to
204 no); 45 mo. (range: 8-204 no) for type I and 24
mo. (range: 7-108 no) for type II. Overall mortality
reached 48% (12/25 patients) with 6 cases in each
subtype of RS. On the other hand, while 8 patients
with UJ (50%) (3 with lymphoma 37%) radical du-
ring follow-up 4 of 9 (44%) without ulcers, also
died. Up to now, 3 patients (12%) developed overt
lymphoma (two T-cell and one B-cell type). One
patient (#17) previously characterized as a type I RS
with UJ, who had been exhaustively explored for
malignant complications, developed an extra-abdo-
minal B-cell lymphoma localized in lymph nodes. It
was diagnosed one year after being successfully trea-
ted with TPN, steroids and immunosupression (cy-
closporin). After a short period on treatment, the
patient regained his original body weight and was
free of symptoms for eight months. The patient did
not respond to chemotherapy and died shortly after
diagnosis of lymphoma. Two other patients develo-
ped an intestinal T-cell lymphoma phenotypically
defined as EATL. One of these cases (#2) has been
previously characterized as type I RS and the other
(#18) as type II. A common finding for the three
patients who developed overt lymphoma was the as-
sociation with UJ. The causes of death were lymp-
homa (n=3), sepsis in the context of a progressive
deterioration without overt malignancies and a se-
vere refractoriness to other treatments including ste-
roids and immunosupression (n=5), due to vascular
causes (n=3) and severe malnutrition (n1). Causes
of death and characteristics of these patients are re-
ported in table 4. The median time from diagnosis
of RS to death was 17mo (range 7 to 204 no) 
Three- and five-yr survival rate for the overall po-
pulation was 60% and 56%, respectively, and there
was no difference between RS type I and type II pa-
tients (table 2). Interestingly, deaths in patients with
monoclonality (type II) seem to occur earlier with
respect to diagnosis of RS than those with type I RS.
In RS type II, all 6 patients died in the first 3 yr-pe-
riod of follow-up compared with 3 of 6 in the RS
type I group. Patients with UJ had a lower but non-
significant 3- and 5-yr survival rate compared with
patient without ulcers (table 3). (fig. 1) 
Therapeutic modalities. A monitored GFD was gi-
ven to all patients and maintained during follow-up
despite a lack of initial response. Steroids were sys-
tematically administered in 24 of 25 patients after
refractoriness to GFD was determined. Only one
patient (#4) was not treated with steroids after an
estimated complete resection of the jejunum contai-
ning ulcers. The patient is still alive only on a GFD
and the molecular assessment of the excised seg-
ment showed aberrant IEL infiltration. Sixteen pa-
tients received nutritional support (4 only received
enteral nutrition and 11 total parenteral nutrition
and/or enteral support) in conjunction with a GFD
and steroids. Finally, in 16 patients we added im-
munomodulation (13 cases were treated with azat-
hioprine, 2 with cyclosporine and 1 case intolerant
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to azathioprine was treated with 6-mercaptopurine).
Three cases did not receive immunomodulators be-
cause of sepsis (two of them developed lymphoma),
2 other because of improvement after steroids and
another due to the complete resection of ulcers and
a positive response to a GFD. Finally, one case had
a progressive nutritional impairment and died. 
Clinical status of survival patients. At December
2004, 13 patients were still alive for a median fo-
llow-up of 66 mo. (range 15 to 156 no) (table 5).
Six of these patients were categorized as RS type I
and seven were RS type II. Molecular analysis of
biopsy samples obtained at the follow-up (n=8) de-
tected persistence of the characteristics assessed in
samples from diagnosis. Histological characteristics
of post-treatment biopsy samples showed marked
improvement in all, with almost complete recovery
in eight. While the clinical condition was conside-
red good or excellent in 11 patients, in 2 other cases
diarrhea still persists 15 and 57 months after diag-
nosis. They required new series of immunosuppres-
sive drugs (6-MP and azathioprine). Another pa-
tient (#9) persists with a low BMI 19 mo after diag-
nosis of RS and 9 mo after immunosuppression was
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Figure 1. Actuarial survival (Kaplan-Meier curves) of
refractory sprue patients assessed from the time of sus-
picion of the complication. A: patients categorized by
presence or absence of monoclonal TCR_ gene rearran-
gement. B: patients categorized by the presence or ab-
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Table 4. Clinical characteristics of 12 RS patients as assessed at the time of death. Patients #2 to #11 have had
an aberrant intraepithelial lymphocyte infiltration determined by molecular biology. Patients #15 to #25 had a
polyclonal population. M and F represent male and female gender. S: steroids; AZP: azathioprine; TPN: total
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and AGA type IgA (6/12 vs. 1/11, respectively)
decreased. (figure 2)
Discussion
Refractory sprue is a rare, poorly understood ma-
labsorption syndrome which is difficult to diagnose,
is lacking a well-established therapy and is characte-
rized by a poorly understood outcome.14 Several aut-
hors agree that there is enough evidence for conside-
All patients follow strict gluten avoidance (table 5).
Comparing final vs. baseline (at diagnosis of RS)
determinations, survival patients significantly im-
proved BMI (18.8±0.8 vs. 24.3±0.7 Kg/m2, respec-
tively; p<0.0001), serum albumin (2.8±0.3 vs.
3.9±0.1 g/dL, respectively; p<0.03) fecal a1 an-
titrypsin clearance (134±21 vs. 16±7 mL/day, res-
pectively; p<0.004), and the number of cases with
positive EmA type IgA (8/12 vs. 0/10; p<0.0004)
Figure 2. Biochemical features (serum albumin and fecal α1 antitrypsin clearance) and body mass index (BMI)
in survivor patients as they were assessed at diagnosis of refractory sprue (Before) and at December of 2004 (After).
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Table 5. Clinical characteristics of 13 surviving RS patients as they were assessed in December of 2004. Patients
#1 to #13 have an aberrant intraepithelial lymphocyte infiltration determined by molecular biology. Patients #14
to #24 have a polyclonal population. M and F represent male and female gender. S: steroids; AZP: azathioprine;
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ring RS as a manifestation of IEL lymphoma (cryp-
tic lymphoma) that in some cases may progress to
overt EATL.8-14 One of the most relevant, still unsol-
ved, topics is whether it represents an evolutionary
state of a pre-existing CD or constitutes a common
final event of a group of heterogeneous conditions
characterized by a celiac-like enteropathy with simi-
lar clinical features and poor prognosis.10,24 In gene-
ral, the prognosis of most patients is severe with a
progressive clinical and nutritional deterioration.9
Information regarding these patients is limited by
the scanty number of cases reported, the difficulties
for diagnosing RS, the diversity of pathobiologic
findings, and the fact that most series are based on
selected patients diagnosed in different centers. 
Herein, we report 25 consecutive patients diagno-
sed at the same institution in whom pre-and post-
diagnostic assessments were performed using a simi-
lar diagnostic and therapeutic approach by the same
physician team. All patients enrolled were exhausti-
vely investigated (with non-invasive and invasive
procedures including laparotomy) in order to exclu-
de the presence of overt lymphoma at the time of
diagnosis of RS. In our opinion, the most relevant
features of the present report were mostly related to
some obscure characteristics of the disorder. Firstly,
one of the most daunting challenges facing clinician
and experienced people is establishing the true pre-
existence of CD in RS patients. In keeping with a
prior experience of French researchers,8,9 we confir-
med that most, if not all patients diagnosed with RS
in this study had evidence of CD, based on histolo-
gical findings, clinical features (response to a GFD,
family history of CD and the presence of CD-spe-
cific antibodies) and the characteristic HLA genoty-
pe. This evidence firmly suggests CD in 22 patients
(IgA EmA and AGA in 19 cases and clinical and
histological response to a gluten-free diet in other
three patients). HLA DQ2 and/or DQ8 were detec-
ted in all the 24 patients typed. 
According to the TCRγ analysis, 12 patients had
a polyclonal lymphocyte population (RS type I) and
13 exhibited monoclonal TCR-γ gene rearrange-
ment characteristic of a RS type II. The almost si-
milar proportion of patients with polyclonal or abe-
rrant monoclonal IEL populations contrasts with
prior experience from other authors who reported
that most well-defined RS patients (>75%) have an
IEL infiltration characterized by morphologically
normal cells expressing intracellular CD3_ recep-
tors but lacking surface CD3, CD4 and CD8 and
having a restricted rearrangement of the gene.8 This
discrepancy between studies seems to be intriguing,
but we suggest that it simply may reflect a selection
bias with an incorrect estimation of the magnitude
of subgroups due to the retrospective nature of stu-
dies. In such context, our study was based on a ro-
bust clinical identification of patients and the sub-
sequent characterization of subgroups using the
molecular analysis of biopsy samples for the clonal
intestinal TCR_ gene rearrangement. Furthermore,
exclusion criteria in our study were limited to the
identification of overt lymphoma at the time of
diagnosis of RS and the lack of CD serology or ge-
notyping. In contrast, prior studies seem to include
patients collected in other centers with potential cli-
nical and diagnostic differences. 
Another interesting feature of the study popula-
tion was the presence of intestinal ulcerations in a
substantial number of patients with RS. Based on
findings from small bowel barium studies, enteros-
copy and laparotomy, 16 patients (64%) had multi-
ple ulcers in the small bowel. In contrast to a prior
report,9 UJ patients were similarly represented in
both types of RS patients (seven in RS type I and
nine in type II). All patients having the suspicion of
intestinal ulcers were exhaustively explored using
either laparotomy (n=6) or enteroscopy (n=5) or
both procedures (n=5) in order to obtain histologi-
cal sampling for establishing the presence of lymp-
homa and genotyping. Our findings are not in
agreement with those reported by Cellier et al.9
where UJ was found only in patients with the cha-
racteristic abnormal clonal T-cell proliferation. We
estimate that a possible explanation for such diffe-
rence with respect to the French study might be at
least partially related to the relatively increased re-
presentation of type I RS in our population. 
Our long-term evaluation confirms that mortality
of patients with RS is high approaching 50%. Mor-
tality was similar in RS type I (50%) and RS type II
(46%). All deaths in RS type II patients occurred in
the first 3-year of follow-up and 3 of 6 patients in
RS type I died during that period. Patients with UJ
had a higher three- and five-yr mortality rates com-
pared with patients without evidence of intestinal
ulcerations, but this was not statistically significant.
Once again, these observations differ from those
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tingly, our population was constituted by an unu-
sual equivalent proportion of RS types I and II
which allowed us to compare both subsets. In this
context, we have shown that both subgroups share a
similar clinical behavior and outcome. Our study
confirms that RS is a severe disorder with very high
mortality, mainly during the first three-year period
after diagnosis of RS. Diagnosis of overt lymphoma
in our long-term follow-up was not as frequent as
reported by other groups. Finally, a proportion of
patients still persist alive for a long time indepen-
dently of the nature of the IEL infiltration. 
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